Literature DB >> 17646416

Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.

Lorna E T Stearne1, Wil H F Goessens, Johan W Mouton, Inge C Gyssens.   

Abstract

The efficacy of beta-lactams is thought to be dependent on the time that the unbound concentrations exceed the MIC (fT>MIC). However, the pharmacokinetic/pharmacodynamic index (PDI) that correlates best to the selection of resistance is not yet clear. The selection of ceftizoxime (CZX)-resistant Enterobacter cloacae mutant strains during the development of murine mixed-infection abscesses was studied to determine the PDI that is important for the emergence of resistance and the PDI value needed for the prevention of resistance. Studies were carried out 24 h after inoculation with Bacteroides fragilis ATCC 23745 and E. cloacae 22491. Six to 1,536 mg of CZX/kg of body weight/day given every 2 h (q2h), q4h, q6h, or q8h was started 30 min before inoculation and continued for 24 h. Resistant mutants were isolated to determine mutant frequencies (MF). The fT>MIC varied from 9 to 98% for E. cloacae, the peak concentration (unbound fraction) was 0.6 to 578 mg/liter, and the area under the concentration-time curve (unbound fraction) (fAUC) was 1.9 to 553 mg.h/liter. The fAUC-to-MIC ratio best explained the in vivo efficacy. CZX-resistant B. fragilis and E. cloacae mutants were isolated from untreated controls at an MF of 10(-5) to 10(-7). The MF of resistant B. fragilis did not increase during therapy. The selection of resistant E. cloacae strains at an MF of 10(-1) to 10(-2) was related to the fT>MIC and the ratio of fAUC to MIC following an inverse U shape. However, the ratio of fAUC to MIC was the stronger driver of resistance. The highest MFs were 0.7 to 0.9 at an fAUC-to-MIC ratio of approximately 250. We conclude that the ratio of fAUC to MIC is the PDI that correlated best to the in vivo efficacy of CZX and probably also to the emergence of resistant E. cloacae mutants. An fAUC-to-MIC ratio of 1,000 was needed to prevent the emergence of this resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646416      PMCID: PMC2043274          DOI: 10.1128/AAC.01486-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations.

Authors:  J W Mouton; A A Vinks
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

2.  Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.

Authors:  J K Thomas; A Forrest; S M Bhavnani; J M Hyatt; A Cheng; C H Ballow; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 3.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

4.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

6.  Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.

Authors:  D Guillemot; C Carbon; B Balkau; P Geslin; H Lecoeur; F Vauzelle-Kervroëdan; G Bouvenot; E Eschwége
Journal:  JAMA       Date:  1998-02-04       Impact factor: 56.272

7.  Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model.

Authors:  J C Pechère; I R Vladoianu
Journal:  J Antimicrob Chemother       Date:  1992-05       Impact factor: 5.790

8.  Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model.

Authors:  F Soriano; P García-Corbeira; C Ponte; R Fernández-Roblas; I Gadea
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

9.  Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection.

Authors:  W H F Goessens; J W Mouton; M T ten Kate; A J Bijl; A Ott; I A J M Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  2007-02-08       Impact factor: 5.790

10.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more
  8 in total

Review 1.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

3.  Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.

Authors:  Jürgen B Bulitta; Jenny C Yang; Liliana Yohonn; Neang S Ly; Silvia V Brown; Rebecca E D'Hondt; William J Jusko; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

4.  Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone.

Authors:  Marco M Custodio; Daniel Sanchez; Beverly Anderson; Keenan L Ryan; Carla Walraven; Renee-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  The path of least resistance: aggressive or moderate treatment?

Authors:  Roger D Kouyos; C Jessica E Metcalf; Ruthie Birger; Eili Y Klein; Pia Abel zur Wiesch; Peter Ankomah; Nimalan Arinaminpathy; Tiffany L Bogich; Sebastian Bonhoeffer; Charles Brower; Geoffrey Chi-Johnston; Ted Cohen; Troy Day; Bryan Greenhouse; Silvie Huijben; Joshua Metlay; Nicole Mideo; Laura C Pollitt; Andrew F Read; David L Smith; Claire Standley; Nina Wale; Bryan Grenfell
Journal:  Proc Biol Sci       Date:  2014-11-07       Impact factor: 5.349

Review 6.  Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction.

Authors:  Ijaz Ahmad; Lingli Huang; Haihong Hao; Pascal Sanders; Zonghui Yuan
Journal:  Biomed Res Int       Date:  2016-02-16       Impact factor: 3.411

7.  Aggressive or moderate drug therapy for infectious diseases? Trade-offs between different treatment goals at the individual and population levels.

Authors:  Jérémie Scire; Nathanaël Hozé; Hildegard Uecker
Journal:  PLoS Comput Biol       Date:  2019-08-12       Impact factor: 4.475

8.  Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?

Authors:  Troy Day; Andrew F Read
Journal:  PLoS Comput Biol       Date:  2016-01-28       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.